GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Capex-to-Revenue

ACADIA Pharmaceuticals (FRA:DR6) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

ACADIA Pharmaceuticals's Capital Expenditure for the three months ended in Mar. 2024 was €0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was €189.37 Mil.

Hence, ACADIA Pharmaceuticals's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


ACADIA Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for ACADIA Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Capex-to-Revenue Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.02 - - 0.06

ACADIA Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ACADIA Pharmaceuticals's Capex-to-Revenue

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Capex-to-Revenue falls into.



ACADIA Pharmaceuticals Capex-to-Revenue Calculation

ACADIA Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-36.726) / 666.143
=0.06

ACADIA Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 189.365
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ACADIA Pharmaceuticals  (FRA:DR6) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


ACADIA Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals (FRA:DR6) Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (FRA:DR6) Headlines

No Headlines